Applies to sars-cov-2 mrna (tozinameran) vaccine: intramuscular suspension.

Local

Very common (10% or more): Pain at injection site (78.3% to 90.5%), injection site swelling (up to 10.5%)

Common (1% to 10%): Swelling, injection site redness/redness^[Ref]

Nervous system

Bell's palsy occurred in 4 patients in the treatment group versus 2 patients in the placebo group. Onset of facial paralysis occurred on day 37 after dose 1 (patient only received one dose), and days 3, 9, and 48 after dose 2 in the treatment group; onset of facial paralysis was day 30 and 102 in the placebo group. Currently available information is insufficient to determine a causal relationship with the vaccine.^[Ref]

Very common (10% or more): Headache (43.5% to 75.5%)

Uncommon (0.1% to 1%): Lethargy

Rare (0.01% to 0.1%): Bell's palsy

Postmarketing reports: Dizziness, syncope^[Ref]

Other

Very common (10% or more): Fatigue (49.4 to 77.5%), use of antipyretic or pain medication (27.8% to 45.2%), fever of 38C or higher (4.1% to 24.3%)

Uncommon (0.1% to 1%): Malaise, asthenia^[Ref]

Musculoskeletal

Very common (10% or more): Chills (16.5% to 49.2%), new or worsened muscle pain (22.9% to 42.2%), new or worsened joint pain (11.8% to 24.3%)

Postmarketing reports: Pain in extremity (arm)^[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (up to 11.7%)

Common (1% to 10%): Nausea, vomiting

Uncommon (0.1% to 1%): Decreased appetite^[Ref]

Hypersensitivity

Postmarketing reports: Severe allergic reactions including anaphylaxis, other hypersensitivity reactions (e.g., rash, pruritus, urticaria, angioedema)^[Ref]

Cardiovascular

Postmarketing reports: Pericarditis, myocarditis^[Ref]

Dermatologic

Uncommon (0.1% to 1%): Hyperhidrosis, night sweats^[Ref]

Hematologic

Uncommon (0.1% to 1%): Lymphadenopathy^[Ref]

Metabolic

Uncommon (0.1% to 1%): Decreased appetite^[Ref]

Frequently asked questions

• Can you take Ibuprofen after the COVID booster vaccine?